Issued jointly by ten bodies (MIIT, NDRC, MNR, MARA, MOFCOM, NHC, MEM, NHSA, NATCM, NMPA), the sectoral plan outlines 2030 objectives: revenue of above-scale pharma enterprises of at least RMB 3.5 trillion, average R&D intensity of at least 10% among listed firms, and first-in-class drugs making up at least 25% of the global total.